Chair and Distinguished Professor
University of Pittsburgh, School of Public Health, Dept of Epidemiology
Dr. Cauley is Distinguished Professor and Interim Chair, Dept of Epidemiology, University of Pittsburgh. Dr. Cauley has been involved in osteoporosis research for over 30 yrs and is the Past-President of the American Society for Bone and Mineral Research (ASBMR). Dr. Cauley is the PI of the Osteoporotic Fractures in Men Study at the University of Pittsburgh, since its inception. She is Dual PI of a funded RO1 entitled, Bone microarchitecture and bone strength: relationships to muscle quantity, quality and function in older adults.
Dr. Cauley also served on several large, multi-site longitudinal studies and clinical trials focusing on issues related to aging and osteoporosis, including as PI of the Study of Osteoporotic Fractures (SOF) (10,366 women age 65+) at the Pittsburgh field site, 1986-2016. SOF evolved from a study focused on osteoporosis to an important study of aging. She was also Co-PI of the Health Aging and Body Composition Study, one of the first studies to quantify intermuscular fat and relate this to disability, fractures and mortality. She served as the clinical site PI of several major randomized clinical trials of treatments for osteoporosis including the Fracture Intervention Trial (FIT) (alendronate) and its extension, FLEX ( FIT Long-term extension study); the Health Outcomes related to Zolendronic acid-Pivotal Fracture Study( HORIZON-PFS); Multiple Outcomes of Raloxifene Evaluation (MORE); the NIA sponsored Testosterone trials and was Co-PI of the Women’s Health Initiative, serving as the Chair or Co-Chair of the Calcium Vitamin D committee for the duration of the trial. She was Chair of the recruitment committee for both the Testosterone Trials and NIA sponsored ENRGIZE trial testing whether fish oil or Losartan reduced inflammation and improved mobility. Currently, she is Co-Chair of an ASBMR Task Force examining the use of race and ethnicity in clinical algorithms related to fracture risk.
Friday, March 31, 2023
2:15 PM – 3:15 PM
Disclosure(s): No financial relationships to disclose